Skip to main content

General principles to address virus and vector shedding

 Addressing virus and vector shedding is a critical consideration in the development and administration of gene therapy and vaccine products. To address this issue, regulatory agencies like the European Medicines Agency (EMA) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) typically provide general principles and guidelines for the development and evaluation of gene therapy and vaccine products. These principles often cover aspects related to virus and vector shedding. Here are some general principles that are commonly applied:


Risk Assessment and Mitigation:

  • Conduct a comprehensive risk assessment to evaluate the potential for virus and vector shedding based on the product's characteristics and mechanism of action.
  • Implement appropriate risk mitigation strategies to minimize the risk of shedding.

Vector Design and Modification:

  • Optimize vector design to reduce the likelihood of shedding. This may involve using self-inactivating vectors or modifying vectors to enhance their safety profile and minimize shedding potential.

Administration Techniques:

  • Follow established guidelines for product administration techniques to reduce the risk of unintended shedding.
  • Consider using specialized equipment or procedures to minimize shedding during administration.

Containment Measures:

  • Use containment measures, where appropriate, during product administration to limit the spread of the vector.
  • Implement procedures to contain and manage any potential shedding events.

Monitoring and Surveillance:

  • Establish a robust monitoring and surveillance program to detect shedding events if they occur.
  • Regularly assess shedding in preclinical studies and clinical trials to understand the shedding profile of the product.

Reporting and Communication:

  • Establish clear reporting procedures for shedding events, adverse events, or unexpected findings.
  • Communicate shedding data transparently to regulatory authorities and the public as necessary, following regulatory requirements and guidelines.

Environmental Impact Assessment:

  • Conduct environmental impact assessments to evaluate the potential consequences of shedding on the environment and neighboring populations.
  • Implement appropriate measures to mitigate environmental risks.

Public Health Measures:

  • Develop public health measures and guidelines for managing contacts of individuals who have received gene therapy or vaccines to minimize the risk of transmission if shedding occurs.

Patient Education:

  • Provide comprehensive information to patients and their caregivers about potential shedding risks and preventive measures.

Regulatory Compliance:

  • Ensure compliance with regulatory requirements and guidelines related to gene therapy and vaccines, which may include specific recommendations for addressing shedding.

Research and Development:

  • Invest in research and development efforts to improve the safety profile of gene therapy and vaccine products, with a focus on minimizing shedding risks.
  • Continual Evaluation:
  • Continually evaluate the safety and shedding characteristics of gene therapy and vaccine products and be prepared to adapt strategies and guidelines as new information becomes available.

Please note that while these are general principles for addressing virus and vector shedding, specific strategies and measures may vary depending on the product, the disease being targeted, and regional regulatory requirements. Close collaboration with regulatory authorities and experts in the field is essential to ensure the safe development and administration of gene therapy and vaccine products

Labels:

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

Guideline on development and manufacture of lentiviral vectors (CHMP/BWP/2458/03)

The guideline with the reference number "CHMP/BWP/2458/03" pertains to the "Guideline on Development and Manufacture of Lentiviral Vectors." This guideline was developed by the Committee for Medicinal Products for Human Use (CHMP) and the Biotechnology Working Party (BWP) of the European Medicines Agency (EMA). It provides recommendations and regulatory guidance for the development and manufacture of lentiviral vectors, which are widely used in gene therapy and cell therapy applications. Here's an overview of the key points covered in this guideline: 1. Introduction: The guideline begins with an introduction highlighting the increasing importance of lentiviral vectors in advanced therapies and the need for guidance on their development and manufacture. 2. Scope: It defines the scope of the guideline, which covers the development and manufacture of lentiviral vectors intended for use in gene therapy and cell therapy products for human use. 3. Quality and Characte...
Read more

Stem-Loop PCR for siRNA

 Stem-loop PCR is a method often used for detecting and quantifying small RNAs, such as siRNA or miRNA, which are typically difficult to amplify directly due to their short lengths. The method involves the design of a stem-loop reverse transcription (RT) primer, which enhances specificity and stability of the short RNA during the RT-PCR process, allowing for sensitive detection and quantification of the siRNA. Here’s a detailed guide to how stem-loop PCR can be applied to siRNA detection: Key Steps in Stem-Loop PCR for siRNA Designing the Stem-Loop RT Primer : Structure : The stem-loop RT primer consists of a loop region flanked by complementary sequences on either side (the "stem"), which will fold back on itself to form a hairpin structure. Specific Binding Region : A short sequence complementary to the 3’ end of the siRNA is added at the end of the stem-loop primer to ensure specific binding to the siRNA target. Stabilization : The loop structure helps prevent primer-dimer...
Read more

FDA Guidance on Studying Multiple Versions of Cellular or Gene Therapy Products in Early-Phase Clinical Trials

 The purpose of this guidance is to offer advice to sponsors interested in conducting early-phase clinical trials for a single disease involving multiple variations of a cellular or gene therapy product. Sponsors aim to gather preliminary safety and efficacy data for these product variations within a single clinical trial. It's important to note that even though multiple product versions are studied together, each version is distinct and typically requires a separate investigational new drug application (IND) submission to the FDA. The primary goal of these early-phase clinical studies is to inform decisions about which product version(s) should be advanced for further development in later-phase trials. As such, these studies are not designed to provide the main evidence of effectiveness needed for a marketing application. They are generally not statistically powered to demonstrate a significant difference in efficacy between the different study arms. In this guidance, the FDA prov...
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quanti...
Read more